CAPLIN POINT LAB LTD.
Latest filings
- Registrar confirms share demat processing for Sep 2026 quarter · Compliance
- Insider trading window closes from Oct 1, 2026 ahead of Q2 and H1 FY26 results · Compliance
- Caplin Point Labs 35th AGM: All 6 resolutions passed with strong majority · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
Sells generic pharmaceutical formulations, including injectable products made by subsidiary Caplin Steriles Limited, primarily to customers in emerging markets and the United States. The 'Rest of the World' segment accounts for 75.3% of segment revenue and the USA segment 19.7%, with a small unallocated portion of 5.0%. The US business operates through Caplin Steriles, which holds 55 ANDA approvals from the USFDA, including a May 2026 approval for Foscarnet Sodium Injection, a generic version of Foscavir targeting a US market of approximately $15 million for the 12 months ending March 2026. On the cost side, materials account for 16.3% of revenue, employee costs 9.1%, and other operating expenses 16.5%, with capex at 11.3% of revenue. The company holds ₹1,471 crores in free cash reserves and ₹2,726 crores in liquid assets, and declared an interim dividend of ₹4 per share (200% on face value of ₹2) for FY26.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from CAPLIN POINT LAB LTD.'s filed financials and exchange disclosures
What does CAPLIN POINT LAB LTD. do?
CAPLIN POINT LAB LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol CAPLIPOINT.
Is CAPLIN POINT LAB LTD. profitable?
Yes. Over the trailing twelve months CAPLIN POINT LAB LTD. reported a net profit of ₹678 Cr on revenue of ₹2,287 Cr.
Does CAPLIN POINT LAB LTD. pay a dividend?
Yes. The dividend yield is 0.25% at the current price. It paid out 7% of its profit as dividend in FY26.
Is CAPLIN POINT LAB LTD. debt-free?
On a net basis, yes. It reported borrowings of ₹0.57 Cr on its 31 Mar 2026 balance sheet, but holds ₹94 Cr more cash than debt.
Is CAPLIN POINT LAB LTD. expensive compared with its peers?
On trailing P/E, CAPLIN POINT LAB LTD. ranks 69 of 158 in Pharmaceuticals — cheaper than 57% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the CAPLIN POINT LAB LTD. share price move in a day?
On a typical session CAPLIN POINT LAB LTD. moves 1.20% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track CAPLIN POINT LAB LTD.'s announcements?
Every NSE and BSE filing by CAPLIN POINT LAB LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.